- Home
- SF vs PEN Comparison
SF vs PEN Comparison
Compare SF & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SF | PEN |
|---|---|---|
| Founded | 1890 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 12.6B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SF | PEN |
|---|---|---|
| Price | $83.73 | $324.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 16 |
| Target Price | $90.33 | ★ $360.14 |
| AVG Volume (30 Days) | ★ 1.0M | 312.7K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | ★ 2.83 | 1.70 |
| Revenue | ★ $6,347,533,000.00 | $1,403,665,000.00 |
| Revenue This Year | $14.58 | $14.34 |
| Revenue Next Year | $8.03 | $13.71 |
| P/E Ratio | ★ $29.68 | $192.45 |
| Revenue Growth | 6.65 | ★ 17.50 |
| 52 Week Low | $67.81 | $221.26 |
| 52 Week High | $134.74 | $362.41 |
Technical Indicators
Market Signals| Indicator | SF | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 69.04 |
| Support Level | $68.36 | $326.58 |
| Resistance Level | $84.33 | $329.67 |
| Average True Range (ATR) | 1.64 | 2.04 |
| MACD | -0.22 | 0.36 |
| Stochastic Oscillator | 60.10 | 80.72 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.